TGN1412 drug molecule. Computer model showing the secondary structure of the drug TGN1412. This drug was shown to have serious side effects during a clinical trial in the UK in 2006 when it caused systemic failure in 6 volunteers. The drug is a monoclonal antibody that activates T cells by binding to CD28 receptors on the cell's surface. T cells are a type of white blood cell and a component of the body's immune system | |
Lizenzart: | Lizenzpflichtig |
Credit: | Science Photo Library / Evans, Dr. Tim |
Bildgröße: | 4172 px × 4170 px |
Modell-Rechte: | nicht erforderlich |
Eigentums-Rechte: | nicht erforderlich |
Restrictions: | - |